Detailed description of dosage, usage and adjustment suggestions during taking furmonertinib

Furmonertinib (Furmonertinib, trade name: Efosa®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations. It can effectively inhibit the activity of EGFR mutant receptors, including the common T790M drug-resistant mutation. According to clinical recommendations, the standard dose of fumetinib is 80 mg, taken orally once a day, with food or on an empty stomach. Patients should take the medicine at a fixed time every day to maintain stable blood concentration and ensure the sustainability of the therapeutic effect.

The dose of fumetinib can be adjusted individually based on the patient's tolerance and adverse reactions. If the patient experiences moderate to severe adverse reactions (such as persistent rash, diarrhea, or abnormal liver function), the doctor can temporarily interrupt the medication and resume treatment after the symptoms subside. If necessary, consider reducing the dose from 80 mg to 40 mg once daily. For patients with good efficacy but poor tolerance, low-dose regimens can still maintain a certain anti-tumor effect. On the contrary, if the patient does not respond adequately to treatment and tolerates it well, some studies have explored the feasibility of increasing the dose to 160 mg once daily, but this must be done under close monitoring by a physician to avoid increased toxicity due to drug accumulation.

For patients with impaired liver and kidney function, there is usually no need to adjust the dosage for mild to moderate injuries, but patients with severe liver or renal dysfunction need to use the drug with caution and regularly monitor blood drug concentrations and biochemical indicators. Elderly patients are recommended to start with a lower dose if their metabolic capacity is reduced. If patients are concurrently taking drugs that may affect the metabolism of fumetinib, such as strong inhibitors (such as ketoconazole) or inducers (such as rifampicin) of CYP3A4, they should consult their doctors to assess the risk of drug interaction and adjust the dose or replace appropriate concomitant drugs if necessary.

Fumetinib should be swallowed whole and should not be broken or chewed to avoid unstable efficacy due to changes in drug exposure. If you miss a dose, you should take it as soon as possible. However, if it is less than 12 hours before the next dose, skip the missed dose and do not double the dose. Liver function, kidney function, electrolytes and electrocardiogram (QT should be tested regularly during treatmentinterval) to allow early detection of potential adverse reactions. Patients should be careful not to take it with grapefruit or foods containing grapefruit ingredients as it may affect drug metabolism. In general, during the use of fumetinib, it is necessary to strictly follow the doctor's instructions, adjust the dose reasonably, and cooperate with regular monitoring to achieve the treatment goals of maximizing efficacy and minimizing adverse reactions.

Reference materials:https://www.drugs.com/